<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Hösli I</dc:creator>
  <dc:creator>Sperschneider C</dc:creator>
  <dc:creator>Drack G</dc:creator>
  <dc:creator>Zimmermann R</dc:creator>
  <dc:creator>Surbek D</dc:creator>
  <dc:creator>Irion O</dc:creator>
  <dc:date>2014</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Tocolysis is an important treatment in the improvement of outcome in preterm labor and preterm birth, provided that its use follows clear evidence-based recommendations. In this expert opinion, the most recent evidence about efficacy and side effects of different tocolytics is being reviewed and evidence-based recommendation about diagnosis and treatment of preterm labor is given. Further aspects such as progesterone administration or antibiotic treatment for the prevention of preterm birth are included. Our review demonstrates that an individualized choice of different tocolytics and additional treatments is necessary to improve short- and long-term neonatal outcome in preterm labor and preterm birth.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/6991</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00404-013-3137-9</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24385286</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Archives of gynecology and obstetrics. - 2014</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Anti-Bacterial Agents</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Bed Rest</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Calcium Channel Blockers</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Cervical Length Measurement</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Contraindications</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Cyclooxygenase Inhibitors</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Drug Approval</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Fenoterol</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Fetal Membranes, Premature Rupture</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Hexoprenaline</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Infant, Newborn</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Kalanchoe</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Labor Stage, First</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Magnesium Sulfate</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Nitric Oxide Donors</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Obstetric Labor, Premature</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Phytotherapy</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Pregnancy</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Premature Birth</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Progesterone</dc:subject>
  <dc:subject xmlns:ns23="xml" ns23:lang="en">Progestins</dc:subject>
  <dc:subject xmlns:ns24="xml" ns24:lang="en">Receptors, Oxytocin</dc:subject>
  <dc:subject xmlns:ns25="xml" ns25:lang="en">Tocolysis</dc:subject>
  <dc:subject xmlns:ns26="xml" ns26:lang="en">Tocolytic Agents</dc:subject>
  <dc:subject xmlns:ns27="xml" ns27:lang="en">Ultrasonography, Prenatal</dc:subject>
  <dc:title xmlns:ns28="xml" ns28:lang="en">Tocolysis for preterm labor: expert opinion.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
